Associated tags: Cell, Patient, Pharmaceutical industry, Gesellschaft mit beschränkter Haftung, Cancer, Biotechnology, Vaccine, Medical imaging, CMSO, TILS, Immunotherapy, Safety, Gene expression, Epic, Glioblastoma
Locations: MA, FLORIDA, VIENNA, AT, AUSTRIA, SAN FRANCISCO, ÖSTERREICH
CEO,
Acute respiratory distress syndrome,
Inhalation,
Arester Earl,
Jazz Pharmaceuticals,
Dinutuximab,
COVID-19,
AGM,
PAH,
Degenerative disease,
GLOBE,
Patient,
Cell,
AG,
Growth,
Gesellschaft mit beschränkter Haftung,
APN01,
Social,
Hypertensive emergency,
Neuroblastoma,
ACE2,
Bossard Holding AG,
IP,
Cancer,
Severe acute respiratory syndrome coronavirus 2,
Pharmaceutical industry,
Vaccine,
Generic drug,
EU Shareholders in APEIRON Biologics AG will be granted shares in invIOs Holding AG pro rata to their current shareholdings in APEIRON Biologics AG.
Key Points:
- Shareholders in APEIRON Biologics AG will be granted shares in invIOs Holding AG pro rata to their current shareholdings in APEIRON Biologics AG.
- AResT will drive the development of APN01, currently being developed for the treatment of COVID-19 and other respiratory and pulmonary indications.
- The new group structure approved by the AGM is an important step forward in enabling our innovation and growth, and we are grateful to our shareholders for their ongoing support.
- APEIRON Biologics is a privately held biotech company based in Vienna, Austria.
Retrieved on:
Thursday, February 3, 2022
EST,
Patient,
Cell,
CET,
Biotechnology,
Cancer,
LSX,
Gotham,
BIO,
CMSO,
Conference,
Pharmaceutical industry,
Management,
Online gambling,
Food delivery,
Vaccine Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO & Investor Conference, Sachs 15th Annual European Life Sciences CEO Forum and LSX World Congress.
Key Points:
- Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO & Investor Conference, Sachs 15th Annual European Life Sciences CEO Forum and LSX World Congress.
- invIOs management will hold company presentations at these events and participate in one panel discussion.
- invIOs is a privately held biotech company based in Vienna, Austria, focused on the discovery and development of innovative cancer immunotherapies.
- Thirdly, the orally administered small molecule candidate INV501 is being developed to target tumor-specific immune activation via a different entry-point.
Retrieved on:
Thursday, February 3, 2022
EST,
Patient,
Cell,
CET,
Gesellschaft mit beschränkter Haftung,
Biotechnology,
Cancer,
LSX,
GLOBE,
Gotham,
BIO,
CMSO,
Conference,
Pharmaceutical industry,
Management,
Online gambling,
Food delivery,
Vaccine invIOs management will hold company presentations at these events and participate in one panel discussion.
Key Points:
- invIOs management will hold company presentations at these events and participate in one panel discussion.
- Company presentation: 14 February at 2:15 pm EST /8:15 pm CET; Room: Gotham
A recorded presentation will be available online for conference participants.
- 01 02 March 2022, virtual
CEO/CFO Peter Llewellyn-Davies will present virtually.
- invIOs is a privately held biotech company based in Vienna, Austria, focused on the discovery and development of innovative cancer immunotherapies.
Retrieved on:
Monday, December 20, 2021
Cancer,
Company,
Severe acute respiratory syndrome coronavirus 2,
Neuroblastoma,
Cell,
Growth,
COVID-19,
CEO,
ACE2,
Biotechnology,
Neoplasm,
Safety,
Patient,
TILS,
APN01,
Gesellschaft mit beschränkter Haftung,
Vaccine,
Pharmaceutical industry,
Medical imaging,
EU,
invIOs GmbH,
APEIRON Biologics AG,
INVIOS GMBH,
APEIRON BIOLOGICS AG The proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enables rapid treatment of patients using their own cells with short out-of-body time in an out-patient setting.
Key Points:
- The proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enables rapid treatment of patients using their own cells with short out-of-body time in an out-patient setting.
- The groundbreaking concept allows access to indications that have previously not been addressable by earlier cell therapy approaches.
- The novel concept allows access to and treatment for indications that had not previously been addressable by cell therapy.
- The second candidate of the platform is INV441, an early-stage cell therapy approach aiming to activate tumor-associated immune cells.
Retrieved on:
Thursday, December 16, 2021
Cancer,
Company,
Severe acute respiratory syndrome coronavirus 2,
Neuroblastoma,
Cell,
Growth,
COVID-19,
CEO,
ACE2,
Biotechnology,
Neoplasm,
Safety,
Patient,
TILS,
GLOBE,
APN01,
Dinutuximab,
Gesellschaft mit beschränkter Haftung,
Pharmaceutical industry,
Medical imaging,
Vaccine,
EU The proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enables rapid treatment of patients using their own cells with short out-of-body time in an out-patient setting.
Key Points:
- The proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enables rapid treatment of patients using their own cells with short out-of-body time in an out-patient setting.
- The groundbreaking concept allows access to indications that have previously not been addressable by earlier cell therapy approaches.
- The novel concept allows access to and treatment for indications that had not previously been addressable by cell therapy.
- The second candidate of the platform is INV441, an early-stage cell therapy approach aiming to activate tumor-associated immune cells.
